1-866-598-7166

Drug Treatment Trials

A Study of 23ME-00610 in Patients with Advanced Kidney Cancer

Background: 23ME-00610 belongs to a class of drugs called immune checkpoint inhibitors. These drugs work by helping to activate the body’s own immune defences in order to target and destroy cancer cells. Some notable approved immune checkpoint inhibitors for kidney cancer include Nivolumab (Opdivo®), Ipilimumab (Yervoy®),...

A Study of Belzutifan + Lenvatinib + Pembrolizumab versus Lenvatinib + Pembrolizumab for Patients with Advanced Kidney Cancer

Background: Lenvatinib (Lenvima®) is a type of tyrosine kinase inhibitor (TKI) that prevents the growth of cancer cells by blocking the formation of new blood vessels in tumours. It is similar to other approved medications such as Sunitinib (Sutent®) or Axitinib (Inlyta®). Pembrolizumab (Keytruda®) is an immunotherapy drug that is...

Kidney Cancer Canada